CUMBERLAND PHARMACEUTICALS INC CPIX
Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us" or "our"), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceuticals. We are dedicated to our mission of working together to provide unique products that improve the quality of patient care.
Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by relatively small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States. We have also established a network of international partners with the needed regulatory and commercial capabilities to register and provide our medicines to patients in their countries.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42.0M | $35.0M | $35.8M | $32.4M | $28.8M | $25.5M | $32.5M |
| Cost of revenue | $6.7M | $6.6M | $6.1M | $9.1M | $8.8M | $8.7M | $7.4M | $6.0M | $5.4M | $6.0M |
| Gross profit | $37.9M | $31.3M | $33.5M | $32.9M | $26.2M | $27.2M | $25.0M | $22.8M | $20.1M | $26.5M |
| R&D | $5.6M | $4.8M | $5.8M | $6.7M | $5.7M | $5.8M | $6.9M | $7.6M | $4.2M | $3.2M |
| SG&A | $11.9M | $11.1M | $10.7M | $10.2M | $9.8M | $10.2M | $10.0M | $10.2M | $9.6M | $8.6M |
| Total operating expenses | $47.3M | $44.3M | $49.1M | $47.7M | $43.7M | $43.8M | $43.7M | $40.5M | $35.2M | $34.5M |
| Operating income | -$2.8M | -$6.4M | -$9.6M | -$5.7M | -$7.7M | -$6.4M | -$9.3M | -$11.2M | -$8.9M | -$1.4M |
| Interest expense | $496.0K | $605.5K | $667.9K | $586.0K | $98.0K | $263.6K | $246.2K | $195.8K | $92.9K | $106.4K |
| Pre-tax income | -$2.8M | -$6.5M | -$6.3M | -$5.6M | -$5.6M | -$6.6M | -$9.3M | -$10.8M | -$8.7M | -$1.3M |
| Income tax | $40.3K | $22.7K | $45.8K | $68.8K | $34.9K | $55.9K | $79.3K | $16.6K | $4.2M | $330.9K |
| Net income | -$2.8M | -$6.5M | -$6.3M | -$5.6M | -$3.5M | -$3.3M | -$3.5M | -$7.0M | -$8.0M | -$944.7K |
| EPS, basic | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 | -0.22 | -0.23 | -0.45 | -0.50 | -0.06 |
| EPS, diluted | -0.19 | -0.46 | -0.44 | -0.38 | -0.24 | -0.22 | -0.23 | -0.45 | -0.50 | -0.06 |
| Shares, diluted (wtd. avg.) | 14.9M | 14.1M | 14.3M | 14.6M | 14.9M | 15.2M | 15.4M | 15.6M | 15.9M | 16.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M | $24.8M | $28.2M | $27.9M | $45.4M | $34.5M |
| Short-term investments | — | — | — | — | — | — | $0 | $8.3M | $4.7M | $15.6M |
| Receivables | $16.9M | $11.7M | $9.8M | $13.2M | $6.9M | $12.4M | $7.9M | $7.8M | $8.4M | $7.3M |
| Inventory | $6.2M | $4.0M | $4.6M | $9.9M | $8.4M | $10.6M | $8.9M | $12.1M | $6.7M | $5.4M |
| Total current assets | $37.1M | $36.5M | $35.7M | $45.9M | $45.7M | $50.0M | $50.2M | $59.1M | $68.7M | $65.5M |
| Property, plant and equipment | $264.7K | $277.4K | $367.9K | $284.0K | $442.6K | $574.2K | $747.8K | $771.2K | $528.9K | $464.5K |
| Goodwill | $914.0K | $914.0K | $914.0K | $914.0K | $882.0K | $882.0K | $882.0K | $784.0K | $0 | — |
| Other intangibles | $14.0M | $18.0M | $22.6M | $30.6M | $24.0M | $28.1M | $30.9M | $33.7M | $21.4M | $22.2M |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M | $96.5M | $104.5M | $112.7M | $93.2M | $93.4M |
| Accounts payable | $18.6M | $13.9M | $14.0M | $10.8M | $9.6M | $13.4M | $10.0M | $11.1M | $9.0M | $8.0M |
| Short-term debt | $0 | $5.1M | $0 | — | — | — | — | — | — | — |
| Total current liabilities | $36.7M | $31.6M | $28.0M | $28.6M | $19.3M | $25.7M | $24.2M | $27.8M | $17.7M | $14.8M |
| Total liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M | $49.6M | $53.5M | $57.1M | $29.3M | $20.3M |
| Retained earnings | -$26.8M | -$24.0M | -$17.5M | -$11.2M | -$5.6M | -$2.1M | $1.2M | $4.7M | $11.7M | $18.6M |
| Total equity | $24.9M | $22.9M | $29.3M | $36.0M | $42.6M | $46.9M | $51.1M | $55.6M | $63.9M | $73.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.9M | -$612.2K | $6.1M | $8.5M | $6.3M | $5.4M | $3.1M | $3.1M | -$557.7K | $569.5K |
| Depreciation and amortisation | $4.1M | $4.9M | $4.9M | $5.3M | $4.6M | $4.7M | $4.4M | $3.0M | $2.6M | $2.4M |
| Stock-based compensation | $408.3K | $301.9K | $365.0K | $447.5K | $741.9K | $1.0M | $1.5M | $1.4M | $1.1M | $852.1K |
| Capital expenditure | $97.9K | $66.5K | $281.3K | $102.1K | $103.5K | $140.8K | $246.2K | $455.6K | $276.0K | $130.9K |
| Investing cash flow | -$4.7M | $57.8K | -$105.7K | -$13.7M | -$501.9K | -$1.8M | $2.3M | -$27.7M | $9.5M | -$3.1M |
| Financing cash flow | -$6.7M | $196.9K | -$7.4M | -$2.1M | -$3.6M | -$7.1M | -$5.1M | $7.1M | $1.9M | -$1.1M |
| Buybacks | $263.5K | $579.0K | $740.5K | $1.1M | $1.4M | $1.9M | $3.5M | $2.9M | $3.7M | $2.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001087294-26-000020.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.5M | $25.5M | $28.8M | $32.4M | $35.8M | $35.0M | $42.0M | $39.6M | $37.9M | $44.5M |
| Gross profit | $26.5M | $20.1M | $22.8M | $25.0M | $27.2M | $26.2M | $32.9M | $33.5M | $31.3M | $37.9M |
| Net income | -$944.7K | -$8.0M | -$7.0M | -$3.5M | -$3.3M | -$3.5M | -$5.6M | -$6.3M | -$6.5M | -$2.8M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Shareholder vote Item 5.07
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |